Clinical trials: Stage I Pancreatic Cancer AJCC v8
Pancreatic Cancer
Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00460174
- Testing
- bevacizumab, gemcitabine, conventional surgery
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Northwestern University
Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors
This phase I trial studies the side effects and best dose of SOR-C13 in treating patients with solid tumors that have spread to other places in the body (advanced) and does not respond to treatment.
- Conditions
- Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Ovarian Carcinoma, Refractory Pancreatic Carcinoma
- Trial name
- NCT03784677
- Testing
- TRPV6 Calcium Channel Inhibitor SOR-C13
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003546
- Testing
- gemcitabine hydrochloride, radiation therapy
- Where
- 48 sites in United States
- Volunteers
- 43 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors.
- Conditions
- Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8
- Trial name
- NCT05040360
- Testing
- Capecitabine, Temozolomide
- Where
- 448 sites in United States, Mexico and 1 more
- Volunteers
- 141 people
- Sponsor
- SWOG Cancer Research Network
Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
This phase I trial evaluates the side effects and best dose of mesothelin-specific T-cells (FH-TCR-Tᴍsʟɴ) in treating patients with pancreatic ductal adenocarcinoma that has spread to other places in the body (metastatic).
- Trial name
- NCT04809766
- Testing
- Autologous Mesothelin-specific TCR-T Cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Fred Hutchinson Cancer Center
Metastatic Malignant Solid Neoplasm, Metastatic Melanoma
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors…
- Conditions
- Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT04119024
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Anusha Kalbasi
Pancreatic Cancer
Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer
This is an open label, phase II trial study of adjuvant GVAX pancreas vaccine in patients with pancreatic cancer.
- Trial name
- NCT00389610
- Testing
- GVAX pancreas vaccine
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Cancer
Gemcitabine and Radiation Therapy in Treating Patients With Cancer of the Pancreas
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Gemcitabine may make tumor cells more sensitive to radiation therapy.
- Trial name
- NCT00010166
- Testing
- gemcitabine hydrochloride, adjuvant therapy, radiation therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Wake Forest University Health Sciences
Pancreatic Cancer
Pancreatic Cancer Collaborative Registry
RATIONALE: Gathering information about patients with cancer may help doctors learn more about the disease and plan early diagnosis and treatment.
- Trial name
- NCT00661882
- Testing
- medical chart review, questionnaire administration, study of socioeconomic and demographic variables
- Where
- United States
- Volunteers
- 379 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Pancreatic Ductal Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8
Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer
This study examines heart rate monitoring variability for the early detection of pancreatic cancer. Pancreatic cancer is a very difficult disease to detect early.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8
- Trial name
- NCT04400903
- Testing
- Activity Monitor, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute
Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
This phase II trial tests how well gemcitabine, cisplatin and nab-paclitaxel given before surgery (neoadjuvant) works in treating patients with pancreatic cancer that can be removed by surgery (resectable) or that is borderline…
- Conditions
- Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8
- Trial name
- NCT06423326
- Testing
- Biopsy, Biospecimen Collection, Cisplatin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Georgetown University
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Resectable Pancreatic Ductal Adenocarcinoma, Stage 0 Pancreatic Cancer AJCC v8
A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer
This phase I trial studies the side effects and best dose of pyrvinium pamoate for the treatment of pancreatic ductal adenocarcinoma that cannot be removed by surgery (resectable).
- Conditions
- Resectable Pancreatic Ductal Adenocarcinoma, Stage 0 Pancreatic Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8, Stage IA Pancreatic Cancer AJCC v8
- Trial name
- NCT05055323
- Testing
- Pyrvinium Pamoate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Thomas Jefferson University
Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
This phase II trial studies the effects of gemcitabine, nab-paclitaxel, durvalumab, and oleclumab in treating patients with primary pancreatic cancer that may be able to be removed by surgery (resectable/borderline resectable).
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8
- Trial name
- NCT04940286
- Testing
- Durvalumab, Gemcitabine, Nab-paclitaxel
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer
Gemcitabine and Radiation Therapy Compared With Gemcitabine Alone in Treating Patients Who Have Undergone Surgery for Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy such as gemcitabine use different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00064207
- Testing
- gemcitabine hydrochloride, adjuvant therapy, radiation therapy
- Where
- 59 sites in Belgium, France and 4 more
- Volunteers
- 97 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Pancreatic Cancer
Laparoscopic Ultrasound in Diagnosing Patients With Pancreatic Cancer
RATIONALE: New diagnostic procedures, such as laparoscopic ultrasound, may improve the ability to detect pancreatic cancer and determine the extent of disease.
- Trial name
- NCT00003085
- Testing
- laparoscopy, ultrasound imaging
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Southern California
Pancreatic Cancer
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an effective immune response to kill pancreatic cancer cells.
- Trial name
- NCT00727441
- Testing
- GVAX pancreatic cancer vaccine, cyclophosphamide
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Cancer
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
RATIONALE: Treating tumor tissue in the laboratory with different drugs may help doctors find the best drug for treating individual patients with pancreatic cancer.
- Trial name
- NCT00276744
- Testing
- cetuximab, capecitabine, docetaxel
- Where
- United States
- Volunteers
- 249 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas
This phase I trial studies the side effects and best dose of GSK525762C (molibresib besylate) and entinostat in treating patients with solid tumors or lymphomas that have spread to other parts of the body (advanced) or are not…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III T-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT03925428
- Testing
- Entinostat, Molibresib
- Sponsor
- National Cancer Institute (NCI)